75 Participants Needed

Flu Vaccine Effectiveness in Aging

(FluVax3 Trial)

LK
GK
Overseen ByGeorge Kuchel, MD, FRCP
Age: 65+
Sex: Any
Trial Phase: Phase 4
Sponsor: The Jackson Laboratory
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop your current medications. However, if you are taking medicines that alter immune response, like high-dose corticosteroids, you may not be eligible to participate.

What data supports the effectiveness of the flu vaccine in preventing hospital admissions?

Preliminary results from the 2014/15 season show that the flu vaccine reduced the chance of hospital admission due to influenza by 44% and was 40% effective in people aged 65 and older.12345

Is the flu vaccine safe for older adults?

The flu vaccines, including the trivalent adjuvanted (aIIV3) and high-dose (HD-IIV3) versions, have been shown to be safe for adults aged 65 and older. Studies indicate that these vaccines maintain a favorable safety profile while providing enhanced immune responses in older adults.678910

How is the flu vaccine treatment unique compared to other treatments for flu prevention?

The flu vaccine treatment is unique because it involves multiple types of vaccines over three years, including high-dose and adjuvanted versions, which are specifically designed to enhance immune response in older adults, making it more effective for aging populations compared to standard flu vaccines.1112131415

What is the purpose of this trial?

This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from participants at seven time-points across the study period. The study is not designed to assess safety or tolerability of the influenza vaccines administered as part of this study.

Research Team

GK

George Kuchel, MD, FRCP

Principal Investigator

UConn Center on Aging

Eligibility Criteria

This trial is for English-speaking men and women aged 65 or older, weighing at least 110 lbs, who are willing to participate in a three-year study involving 19 visits. Participants must be open to receiving annual flu vaccines and providing blood samples. They should not have severe reactions to past flu vaccines but cannot join if they've had Guillain-Barre syndrome after vaccination, recent other vaccinations, egg allergies, certain chronic diseases, or conditions affecting the immune system.

Inclusion Criteria

Able to speak and read English
I agree not to get any vaccines 2 weeks before and after my flu shots for the next three flu seasons.
I am 65 years old or older as of September 1, 2022.
See 6 more

Exclusion Criteria

You are allergic to eggs or any ingredient in the flu vaccine.
I have not received any vaccines within 2 weeks before my flu shot for the 2022-25 seasons.
I have received the flu vaccine for the 2022-23 season.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Vaccination Year 1

Participants receive the Fluzone Quadrivalent High-Dose vaccine and undergo blood sampling for antibody and immune cell analysis

6 months
6 visits (in-person)

Vaccination Year 2

Participants receive the FLUAD Quadrivalent vaccine and undergo blood sampling for antibody and immune cell analysis

6 months
6 visits (in-person)

Vaccination Year 3

Participants receive the Flublok Quadrivalent vaccine and undergo blood sampling for antibody and immune cell analysis

6 months
6 visits (in-person)

Follow-up

Participants are monitored for immune response and effectiveness after each vaccination year

6 months
1 visit (in-person)

Treatment Details

Interventions

  • Flu Vaccine (Year 1)
  • Flu Vaccine (Year 2)
  • Flu Vaccine (Year 3)
Trial Overview The study aims to understand why older adults may have a reduced response to influenza vaccines by administering different flu shots over three years. It involves regular collection of blood samples as well as nasal swabs and stool samples at specific times during the study period.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Healthy Older AdultsExperimental Treatment3 Interventions
Will receive FDA-approved influenza vaccine (Fluzone HD Year 1, FLUAD Year 2, Flublok Quadrivalent Year 3)

Flu Vaccine (Year 1) is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸
Approved in United States as Fluzone High-Dose for:
  • Prevention of influenza A and B in individuals 65 years and older
🇪🇺
Approved in European Union as Fluad for:
  • Prevention of influenza A and B in adults 65 years and older
🇨🇦
Approved in Canada as Fluvirin for:
  • Prevention of influenza A and B in individuals 6 months and older, including those 65 years and older
🇯🇵
Approved in Japan as Fluarix Tetra for:
  • Prevention of influenza A and B in individuals 6 months and older, including those 65 years and older

Find a Clinic Near You

Who Is Running the Clinical Trial?

The Jackson Laboratory

Lead Sponsor

Trials
6
Recruited
2,200+

University of Chicago

Collaborator

Trials
1,086
Recruited
844,000+

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator

Trials
3,361
Recruited
5,516,000+

UConn Health

Collaborator

Trials
218
Recruited
59,100+

Icahn School of Medicine at Mount Sinai

Collaborator

Trials
933
Recruited
579,000+

Weill Medical College of Cornell University

Collaborator

Trials
1,103
Recruited
1,157,000+

Findings from Research

In a study of 233 patients with lumbar foraminal stenosis (LFS), selective nerve root block (SNRB) significantly reduced pain by 51% after just 2 weeks, indicating its efficacy as a treatment option.
Patients with lower grades of LFS (1T, 2, 3) experienced greater and more sustained symptomatic improvement compared to those with grade IV LFS, highlighting the importance of stenosis severity in treatment outcomes.
Comparison of Pain-reducing Effect After Selective Nerve Root Block According to the Type of Lumbar Foraminal Stenosis.Ko, S., Kwon, J., Lee, Y., et al.[2020]
Stage III lung cancer, which includes both IIIa and IIIb, accounts for about one third of all non-small-cell lung cancer cases, with 40,000 to 50,000 new diagnoses each year.
Current treatment strategies for stage III lung cancer involve surgery combined with chemotherapy and/or radiation for stage IIIa, while stage IIIb primarily relies on chemoradiation, with ongoing clinical trials exploring targeted therapies and improved radiation techniques to reduce tumor failures.
Combined modality therapy for stage III non-small-cell lung cancer.Anderson, CS., Curran, WJ.[2010]
A study of 1,553 patients with stage III melanoma found that their 5-year melanoma-specific survival (MSS) rates were lower than those reported in the American Joint Committee on Cancer (AJCCv8) guidelines, indicating a need for improved treatment strategies.
Specifically, the MSS rates for stage IIIA and IIIB patients were significantly less favorable in the Central Malignant Melanoma Registry cohort compared to AJCCv8, highlighting the ongoing challenges in managing these melanoma stages despite recent therapy advancements.
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.Garbe, C., Keim, U., Suciu, S., et al.[2021]

References

Comparison of Pain-reducing Effect After Selective Nerve Root Block According to the Type of Lumbar Foraminal Stenosis. [2020]
Combined modality therapy for stage III non-small-cell lung cancer. [2010]
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. [2021]
Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. [2019]
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. [2019]
Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. [2019]
Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. [2010]
Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial. [2021]
Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications. [2021]
Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States. [2022]
Effect of combination therapy with thyroxine (T4) and 3,5,3'-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. [2022]
Combination L-T3 and L-T4 therapy for hypothyroidism. [2013]
Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. [2022]
Optimal differentiated thyroid cancer management in the elderly. [2018]
A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security